Nexalis TherapeuticsASX:NX1 +8.33% Current Ratio is 0.58 as of Dec. 2025, which is 90% below its 10-year median of 5.99. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Nexalis Therapeutics ranks worse than 89.94% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Nexalis Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 0.58.
Nexalis Therapeutics has a current ratio of 0.58. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Nexalis Therapeutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Nexalis Therapeutics's Current Ratio or its related term are showing as below:
ASX:NX1'
s Current Ratio Range Over the Past 10 Years
Min: 0.58 Med: 5.99 Max: 11.58
Current: 0.58
During the past 10 years, Nexalis Therapeutics's highest Current Ratio was 11.58. The lowest was 0.58. And the median was 5.99.
ASX:NX1's Current Ratio is ranked worse than 89.94% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs ASX:NX1: 0.58
Nexalis Therapeutics (ASX:NX1) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Nexalis Therapeutics Current Ratio Related Terms
Nexalis Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Nexalis Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NX1 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Nexalis Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalis Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nexalis Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Nexalis Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexalis Therapeutics (ASX:NX1) has a Current Ratio of 0.58 as of Dec. 2025. This is 90% below median its historical median of 5.99. Over the past decade, Nexalis Therapeutics' Current Ratio has ranged from 0.58 to 11.58. According to the industry distribution chart, Nexalis Therapeutics ranks #1270 out of 1412 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Nexalis Therapeutics' Current Ratio too high?
Nexalis Therapeutics' current Current Ratio of 0.58 is 90% below median its 10-year median of 5.99. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 11.58. The Biotechnology industry median Current Ratio is 3.90. Nexalis Therapeutics' value of 0.58 is 85.1% below this industry median. Based on the distribution chart, Nexalis Therapeutics ranks #1270 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nexalis Therapeutics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nexalis Therapeutics ranks #1270 out of 1412 companies for Current Ratio. This places Nexalis Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.90. Nexalis Therapeutics' value of 0.58 is 85.1% below this benchmark. Historically, Nexalis Therapeutics' own Current Ratio has ranged from 0.58 to 11.58 over the past decade. While the company's 10-year median is 5.99 vs. the industry median of 3.90, Nexalis Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexalis Therapeutics's current Current Ratio of 0.58 is 85.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexalis Therapeutics's current Current Ratio is 0.58, which is 90% below median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current Current Ratio of 0.58. The current Current Ratio is 0.58, which is 90% below median its 10-year median of 5.99 and 85.1% below the Biotechnology industry median of 3.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current Current Ratio is 0.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NX1 has been successfully added to your 